Lyra Therapeutics Inc. (LYRA) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Lyra Therapeutics Inc.

    NASDAQ: LYRA · Real-Time Price · USD
    6.96
    0.36 (5.45%)
    At close: Sep 09, 2025, 3:59 PM
    6.57
    -5.60%
    Pre-market: Sep 10, 2025, 08:00 AM EDT

    Lyra Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 1.53M 1.56M 1.36M 285K
    Cost of Revenue
    		 n/a 48.03M 1.07M 29.69M
    Gross Profit
    		 1.53M 1.56M 296K -716K
    Operating Income
    		 -96.35M -67.12M -56.31M -43.62M
    Interest Income
    		 2.95M 4.5M 1.04M 102K
    Pretax Income
    		 -93.4M -62.62M -55.27M -43.51M
    Net Income
    		 -93.44M -62.68M -55.28M -43.51M
    Selling & General & Admin
    		 18.5M 19.06M 17.56M 14.21M
    Research & Development
    		 43.77M 48.03M 38.8M 29.69M
    Other Expenses
    		 -471K -46.44M -37.48M -1M
    Operating Expenses
    		 61.8M 20.65M 18.87M 42.9M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 97.88M 68.68M 57.67M 43.9M
    Income Tax Expense
    		 39K 59K 13K n/a
    Shares Outstanding (Basic)
    		 65.11M 49.75M 30.24M 12.99M
    Shares Outstanding (Diluted)
    		 65.11M 49.8M 30.24M 12.99M
    EPS (Basic)
    		 -1.43 -1.26 -1.83 -3.35
    EPS (Diluted)
    		 -1.43 -1.26 -1.83 -3.35
    EBITDA
    		 -60.26M -65.25M -53.92M -42.61M
    EBIT
    		 -60.73M -65.53M -54.99M -43.62M
    Depreciation & Amortization
    		 471K 278K 1.07M 1M

    Add to Watchlist